Printer Friendly
The Free Library
4,656,208 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

AVANIR Licenses Docosanol 10% Cream in Europe.


SAN DIEGO -- AVANIR Pharmaceuticals (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:AVNR AVNR Atrioventricular Nodal Reentry ) announced today that it has signed an exclusive agreement with Healthcare Brands International (HBI HBI Home Builders Institute
HBI Hot Briquetted Iron (plant or facility)
HBI Health and Biomedical Information
HBI Hot Beef Injection (band)
HBI Healthcare Building Ideas (magazine) 
) to develop and market AVANIR's docosanol 10% cream (docosanol) as a treatment for cold sores in the European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the

European Community
, (with the exception of Denmark, Finland, Greece, Italy, and Sweden, all of which are covered by previous license grants from AVANIR) Russia and the Ukraine.

The agreement provides for AVANIR to receive an upfront fee at signing plus milestone payments if docosanol receives certain regulatory approvals in the licensed territory. Additionally, if there is any subsequent divestiture or sublicense of docosanol by HBI (including through a sale of HBI), or any initial public offering of HBI's securities, AVANIR will receive a payment calculated based on a percentage of the assigned value of docosanol to the overall value of the transaction. HBI will be responsible for all expenses related to the regulatory approval and commercialization of docosanol in the territory. "With the completion of this agreement, AVANIR has successfully licensed the rights to docosanol in all significant commercial territories worldwide," said Marty Emanuele, Ph.D., Vice President of Business Development and Licensing at AVANIR.

Docosanol is sold in North America under the brand name abreva(R) by AVANIR's licensee, GlaxoSmithKline Consumer Healthcare, and is the only cold sore product approved by the U.S. Food and Drug Administration (FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
) that is available without a prescription.

About AVANIR

AVANIR Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system, cardiovascular disorders, inflammation and infectious diseases. AVANIR currently markets FazaClo(R), the only orally-disintegrating formulation of clozapine clozapine /clo·za·pine/ (klo´zah-pen) a sedative and antipsychotic agent; used in the treatment of schizophrenia.

clo·za·pine
n.
 for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenic drug treatments. FazaClo is also indicated for reducing the risk of suicidal behavior in patients with schizophrenic or schizoaffective disorder Schizoaffective Disorder Definition

Schizoaffective disorder is a mental illness that shares the psychotic symptoms of schizophrenia and the mood disturbances of depression or bipolar disorder.
. For full prescribing information and important safety information regarding FazaClo, please visit www.fazaclo.com AVANIR's lead product candidate, Neurodex(TM) for the treatment of involuntary emotional expression disorder, is the subject of a New Drug Application under priority review with the FDA. Additionally, AVANIR has initiated a Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the  with Neurodex as a potential treatment for patients with painful diabetic neuropathy Diabetic Neuropathy Definition

Diabetic neuropathy is a nerve disorder caused by diabetes mellitus. Diabetic neuropathy may be diffuse, affecting several parts of the body, or focal, affecting a specific nerve and part of the body.
. AVANIR has active collaborations with two international pharmaceutical companies: Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease and AstraZeneca for the treatment of cardiovascular disease Cardiovascular disease
Disease that affects the heart and blood vessels.

Mentioned in: Lipoproteins Test

cardiovascular disease 
. The Company's first commercialized product, abreva(R), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.

Forward Looking Statements

Statements in this press release that are not historical facts, including statements that are preceded by, followed by, or that include such words as "estimate", "anticipate", "believe", "plan", or "expect", or similar statements, are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from the future results expressed or implied by such statements. There can be no assurance that docosanol will receive additional regulatory approvals in the licensed territories or that we will receive any additional amounts under our license with HBI. Risks and uncertainties also include the risks set forth in AVANIR's most recent Annual Report on Form 10-K Form 10-K

A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information.


Form 10-K

See 10-K.
 and subsequent Quarterly Reports on Form 10-Q and from time-to-time in other publicly available information regarding the Company. Copies of this information are available from AVANIR upon request. AVANIR disclaims any intent or obligation to update these forward-looking statements.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 6, 2006
Words:601
Previous Article:Metropolitan Health Networks to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference in New York.
Next Article:Nara Bancorp to Webcast Review of Second Quarter Fiscal 2006 Financial Results on Thursday, July 27, 2006.



Related Articles
AVANIR Obtains First European Marketing Approval for Docosanol 10% Cream for Cold Sores; Sweden is Lead Country in European Mutual Recognition...
AVANIR Pharmaceuticals Reports First Quarter of Fiscal Year 2004 Results.
AVANIR Signs Agreement with Gerolymatos to Market Docosanol 10% Cream.
AVANIR Signs Agreement With ACO HUD To Market Docosanol 10% Cream in Scandanavia.
AVANIR Pharmaceuticals Reports Fourth Quarter and Fiscal 2004 Year End Results.
AVANIR Pharmaceuticals Reports First Quarter of Fiscal Year 2005 Results.
AVANIR Licenses Docosanol 10% Cream in Japan.
AVANIR Pharmaceuticals Reports First Quarter of Fiscal Year 2006 Results.
AVANIR Pharmaceuticals Reports Second Quarter of Fiscal 2006 Financial Results.
AVANIR Pharmaceuticals Reports Third Quarter Fiscal 2006 Financial Results.

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles